Pulmatrix (PULM) Competitors $7.70 +0.03 (+0.39%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$7.71 +0.01 (+0.12%) As of 01/31/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends PULM vs. PYXS, PWUP, INZY, EPRX, IMAB, XFOR, SCLX, IMUX, GNLX, and SKYEShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include Pyxis Oncology (PYXS), PowerUp Acquisition (PWUP), Inozyme Pharma (INZY), Eupraxia Pharmaceuticals (EPRX), I-Mab (IMAB), X4 Pharmaceuticals (XFOR), Scilex (SCLX), Immunic (IMUX), Genelux (GNLX), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Pyxis Oncology PowerUp Acquisition Inozyme Pharma Eupraxia Pharmaceuticals I-Mab X4 Pharmaceuticals Scilex Immunic Genelux Skye Bioscience Pulmatrix (NASDAQ:PULM) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings. Which has preferable valuation and earnings, PULM or PYXS? Pulmatrix has higher earnings, but lower revenue than Pyxis Oncology. Pulmatrix is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmatrix$7.30M3.85-$14.12M-$2.64-2.92Pyxis Oncology$16.15M5.78-$73.79M-$1.03-1.52 Is PULM or PYXS more profitable? Pyxis Oncology has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Pyxis Oncology's return on equity of -36.22% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets Pulmatrix-96.51% -45.97% -30.72% Pyxis Oncology N/A -36.22%-28.76% Which has more volatility and risk, PULM or PYXS? Pulmatrix has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Does the media favor PULM or PYXS? In the previous week, Pulmatrix had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Pulmatrix and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat Pulmatrix's score of 0.65 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Overall Sentiment Pulmatrix Positive Pyxis Oncology Very Positive Do analysts recommend PULM or PYXS? Pyxis Oncology has a consensus price target of $9.00, indicating a potential upside of 473.25%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the MarketBeat Community prefer PULM or PYXS? Pulmatrix received 168 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 82.35% of users gave Pyxis Oncology an outperform vote while only 48.28% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformPulmatrixOutperform Votes19648.28% Underperform Votes21051.72% Pyxis OncologyOutperform Votes2882.35% Underperform Votes617.65% Do insiders and institutionals hold more shares of PULM or PYXS? 11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 9.8% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryPyxis Oncology beats Pulmatrix on 14 of the 18 factors compared between the two stocks. Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.11M$6.86B$5.56B$9.11BDividend YieldN/A2.90%5.31%3.98%P/E Ratio-2.929.9789.9918.25Price / Sales3.85287.761,243.2883.75Price / CashN/A73.5045.9637.70Price / Book1.565.275.124.71Net Income-$14.12M$136.98M$111.09M$224.24M7 Day Performance5.77%-0.62%2.38%1.08%1 Month Performance10.32%0.15%3.20%1.51%1 Year Performance345.09%7.68%24.70%20.44% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.2116 of 5 stars$7.70+0.4%N/A+345.1%$28.85M$7.30M-2.9220Short Interest ↓News CoverageGap DownPYXSPyxis Oncology2.241 of 5 stars$1.50+2.0%$9.43+528.6%-58.8%$89.21MN/A-1.4660News CoverageGap DownPWUPPowerUp AcquisitionN/A$11.47+0.2%N/A+18.6%$89.12MN/A0.00N/APositive NewsHigh Trading VolumeINZYInozyme Pharma3.35 of 5 stars$1.36flat$18.33+1,248.0%-73.8%$87.37MN/A-0.8750Short Interest ↑Gap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals3.6191 of 5 stars$3.20+6.3%$9.00+181.3%N/A$87.30MN/A-4.4429Positive NewsGap DownIMABI-Mab2.8509 of 5 stars$1.07-2.7%$8.00+647.7%-42.4%$87.21M$3.89M0.00380Short Interest ↑XFORX4 Pharmaceuticals4.3172 of 5 stars$0.51+10.1%$3.50+589.5%-10.4%$86.57MN/A-5.6480Gap DownSCLXScilex3.697 of 5 stars$0.45-4.3%$11.33+2,424.1%-74.9%$86.11M$46.74M-0.3180Gap DownIMUXImmunic3.7144 of 5 stars$0.95-3.4%$12.67+1,229.1%-17.6%$85.85MN/A-0.7770Analyst UpgradeShort Interest ↓News CoverageHigh Trading VolumeGNLXGenelux2.0066 of 5 stars$2.46-0.8%$18.25+641.9%-62.7%$84.97M$170,000.00-2.5910Positive NewsSKYESkye Bioscience1.4478 of 5 stars$2.63-3.6%$18.67+609.0%-19.3%$84.04MN/A0.0011News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Pyxis Oncology Alternatives PowerUp Acquisition Alternatives Inozyme Pharma Alternatives Eupraxia Pharmaceuticals Alternatives I-Mab Alternatives X4 Pharmaceuticals Alternatives Scilex Alternatives Immunic Alternatives Genelux Alternatives Skye Bioscience Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PULM) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
